Lupien P J, Moorjani S, Brun D, Bielmann I
J Clin Pharmacol. 1979 Feb-Mar;19(2-3):120-6. doi: 10.1002/j.1552-4604.1979.tb02469.x.
Different doses of 3-hydroxy-3-methyl-glutaric acid (HMG) on plasma lipids were studied in a double-blind trial in 36 patients with familial hypercholesterolemia (type IIa or hyper-beta-lipoproteinemia). The patients were randomly assigned to five groups, and each group received one of the following treatments: placebo, or HMG 750 mg, 1500 mg, 2250 mg, or 3000 mg per day. As compared to placebo, the mean plasma cholesterol levels during the eight-week treatment period were 11 and 13 per cent lower in the 2250-mg and 3000-mg HMG-treated groups (P less than 0.034 and less than 0.021, respectively). At the same dosage levels LDL cholesterol was decreased by 8 per cent. HMG had no significant effect on plasma triglycerides as compared to placebo. Discontinuation of the medication did not result in a rebound of plasma cholesterol. There were no clinical or biologic adverse effects due to the administration of HMG, and all patients maintained excellent compliance to the medication. Because of its lack of toxicity, HMG may be useful as an adjunct to diet in the treatment of familial hypercholesterolemia.
在一项针对36例家族性高胆固醇血症（IIa型或高β脂蛋白血症）患者的双盲试验中，研究了不同剂量的3-羟基-3-甲基戊二酸（HMG）对血脂的影响。患者被随机分为五组，每组接受以下一种治疗：安慰剂，或每天750毫克、1500毫克、2250毫克或3000毫克的HMG。与安慰剂相比，在为期八周的治疗期间，2250毫克和3000毫克HMG治疗组的平均血浆胆固醇水平分别降低了11%和13%（P分别小于0.034和小于0.021）。在相同剂量水平下，低密度脂蛋白胆固醇降低了8%。与安慰剂相比，HMG对血浆甘油三酯没有显著影响。停药后血浆胆固醇没有反弹。服用HMG没有临床或生物学不良反应，所有患者对药物的依从性都很好。由于其无毒性，HMG可能作为饮食辅助手段用于治疗家族性高胆固醇血症。
